Related Experiment Video

Updated: Jul 15, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Optimal duration of therapy in HBV-related cirrhosis

Carmen Y Lim1, Kris V Kowdley

  • 1University of Washington Medical Center, Box 356174, 1959 NE Pacific Street, Seattle, WA 98195, USA.

The Journal of Antimicrobial Chemotherapy
|May 8, 2007
PubMed

Insights

Chronic hepatitis B affects millions globally, increasing liver cancer risk. Antiviral therapy is recommended for advanced fibrosis, though treatment thresholds require further clarification for optimal patient outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Oncology

Background:

  • Hepatitis B virus (HBV) infection impacts one-third of the global population, leading to chronic hepatitis B in 300-400 million individuals.
  • Chronic HBV is a primary cause of liver disease complications and hepatocellular carcinoma (HCC) in endemic regions.
  • Viral replication levels, particularly HBV DNA >10^4 copies/mL, independently predict future HCC and cirrhosis development.

Framework:

  • Recent antiviral therapies show promise in reducing liver disease decompensation and HCC risk in patients with advanced hepatic fibrosis.
  • New antiviral medications have been approved for chronic hepatitis B treatment.
  • Guidelines recommend oral antiviral therapy for chronic hepatitis B, but optimal treatment initiation and duration remain debated.

Implementation:

  • This article reviews current therapeutic recommendations for chronic hepatitis B patients with cirrhosis or advanced fibrosis.
  • It proposes criteria for initiating antiviral treatment in this patient group.
  • Focus is on managing viral load and disease progression.

Implications:

  • Clarifying treatment thresholds and duration can optimize patient management and reduce long-term complications.
  • Effective antiviral therapy can mitigate the risk of HCC and end-stage liver disease.
  • Standardized treatment criteria will improve clinical outcomes for individuals with chronic hepatitis B-related liver disease.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...